21 Dec 2018

Allergan Impact Study

The ABS circulated the attached message to its members on the 21st December

Allergan Impact Study


The withdrawal of Allergan textured breast implants and tissue expanders is likely to have an immediate and significant impact on UK breast services.  The Association of Breast Surgery in collaboration the Breast and Cosmetic Implant Registry and the other relevant specialist associations (BAPRAS and BAAPS) wish to measure the impact this has on breast services.

For those services which regularly use Allergan textured implants we would like to invite ABS members to submit data regarding the impact on their breast service.  It would be helpful if each centre wishing to collect and submit data could inform Graeme Perks of a key contact from their service to liaise with.  The data items described below will need to be collected, summarised on this excel spreadsheet until the end of January 2019.


Thank you in anticipation of your assistance.

Mark Sibbering, President

Lee Martin, Chair, Aesthetic Breast Surgery Committee



Allergan Textured Devices

Please state the number of textured devices (implants and tissue expanders): 

Bank stock:        
Sale or return /owned:

Impact on Patient Care

Where directly attributable to withdrawal of Allergan textured devices (implants and tissue expanders): 

Number of cancelled operations

Number where a change of plan required

Number where a resultant delay to breast cancer treatment and number days delay

Procurement substitute problems
Please record any issues with procurement of alternative devices

Enquiries / Referrals
Number of patient enquiries 
Time taken to answer (total in minutes)
Number of GP enquiries 
Time taken to answer (total in minutes)
Number of GP referrals

Number of other referrals